Search PubMed⌕ Search

Biomedical subjects

H W Herr

Publications and source records attributed to H W Herr.

At least 235 records · Page 13Linked to original sources
PubMed1981

Radiation-induced sarcoma following radiotherapy for testicular tumor.

We report 4 cases of soft tissue sarcoma following radiation therapy for testicular tumor. The tumors included leiomyosarcoma, fibroxanthosarcoma, reticulum cell sarcoma and spindle cell sarcoma. Each malignancy arose within the irradiated area after a long latent period (mean 12 years) and each was histologically proved. Total radiation doses ranged from 3,500 to 9,000 rad. Three patients died as a result of the second neoplasm. Radiation-induced sarcomas are rare but must be considered in the differential diagnosis of new tumor growth in patients treated previously with radiotherapy. Full evaluation of such new tumor growth, including tissue diagnosis, is necessary before additional therapy is prescribed.

Adult↗
PubMed1981

VAB-6 combination chemotherapy in disseminated cancer of the testis.

Twenty-nine men with stage III or unresectable stage II malignant germ cell tumors and no previous chemotherapy received treatments with the VAB-6 protocol. The VAB-6 regimen is a 1-year program beginning with three successive inductions at 3-to-4-week intervals: day 1--cyclophosphamide, 600 mg/m of body surface area intravenously, bleomycin, 30 mg intravenously, dactinomycin, 1 mg/m2 intravenously, and vinblastine, 4 mg/m2 intravenously; days 1 through 3--bleomycin, 20 mg/m2 . d by continuous infusion; and day 4--cisplatin, 120 mg/m2 intravenously. Bleomycin is omitted from the third induction. One month after the third induction, any residual disease is resected. If the resected specimen contains malignant tissue, an additional two inductions are given before maintenance with vinblastine, 6 mg/m2 intravenously, and dactinomycin, 1 mg/m2 intravenously, every 3 weeks. Of 25 patients with evaluable records, 23 achieved complete remission, and 21 remain in complete remission (median follow-up, more than 16 months). Myelosuppression is the major toxicity. With VAB-6 response rate is high, and treatment is short and better tolerated than with previous VAB protocols.

Antineoplastic Agents↗
PubMed1980

Spontaneous regression of pulmonary metastases from transitional cell carcinoma.

Spontaneous regression of metastatic cancers occurs rarely and has been reported only once for pulmonary metastases from transitional cell carcinoma. Two cases of spontaneous complete regression of lung metastases from transitional cell carcinoma are presented. In one case, regression occurred after a course of radiation to the primary bladder cancer, but in the other patient, lung lesions disappeared without treatment to the primary or metastatic cancers. The factors that alter the tumor-host relationship to allow spontaneous regression of cancers are unknown, but observation of these phenomena may help reveal parameters that influence tumor progression in the majority of cancer patients.

Aged↗
PubMed1980

Ganglioneuroma arising in accessory adrenal gland.

We believe a first case of ganglioneuroma arising in an accessory adrenal gland is reported. Evidence suggests the ganglioneuroma is a benign tumor of neural crest origin that arises by spontaneous maturation from malignant neuroblastoma.

Adrenal Gland Neoplasms↗
PubMed1980

Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer.

There were 21 patients with advanced, measurable bladder cancer who were treated with cis-diamminedichloride platinum II. Of the 21 patients 3 (14 per cent) achieved a complete response that persisted for more than 1 year, while 6 (29 per cent) achieved a partial remission for an average duration of 5.7 months. Responses to cis-diamminedichloride platinum II were noted shortly after administration of the drug. After the initial response no additional benefit of cis-diamminedichloride platinum II was observed after 9 weeks (third dose). Despite the fact that cis-diamminedichloride platinum II was tolerated reasonably well by the majority of patients and that there were 3 cases of long-term remission cis-diamminedichloride platinum II appears limited to induction of a response in patients with advanced bladder cancer rather than for long-term maintenance therapy.

Aged↗
PubMed1980

Suppressor cells in immunodepressed bladder and prostate cancer patients.

Peripheral blood lymphocytes from 23 patients with bladder and prostate cancer were tested for their ability to respond in vitro to phytohemagglutinin, concanavalin A and allogeneic cells. The lymphocyte response was depressed in 15 patients (65 per cent), 13 with advanced disease, compared to peripheral blood lymphocytes from age-matched hospitalized control subjects tested on the same day. Furthermore, the hyporesponsive lymphocytes from 11 of the 15 cancer patients (73 per cent) inhibited the phytohemagglutinin, concanavalin A and mixed lymphocyte culture reactivity of normal lymphocytes in co-cultures (16 to 78 per cent suppression). In contrast, lymphocytes from control donors caused no suppression. Incubation of the patients' unseparated peripheral blood lymphocytes on plastic to remove adherent cells restored lymphocyte responsiveness and eliminated their suppressor activity. Returning the adherent cells to cultures with patients' autologous separated and normal lymphocytes recaptured the suppressive effect. Pre-incubation of the patients' lymphocytes with concanavalin A markedly enhanced their ability to suppress and induced moderate suppressor activity by normal lymphocytes. These data suggested that 1 mechanism for the depression of cell-mediated immunity seen in patients with advanced urological cancer may be owing to non-specific suppressor cells, possibly monocytes.

Humans↗
PubMed1979

Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment.

Peripheral neuropathy developed in two cases of recurrent bladder carcinoma treated with Cis-dichlorodiammineplatinum (II) (DDP) at a dose of 75 mg/m2 IV every 3 weeks. The neuropathy appeared in both patients while they were achieving a subjective and objective response to DDP. The neuropathy was reversible in one patient. In the other patient, a disabling sensory neuropathy progressed despite cessation of therapy. The temporal relationship between the neurological symptoms and the administration of DDP implicate this drug as the possible causative agent in the peripheral neuropathy.

Aged↗
PubMed1979

Suppressor cells in the pelvic lymph nodes regional to bladder cancer.

Regional lymph node cells from some patients with locally advanced bladder carcinoma were found to inhibit the reactivity of normal and autologous peripheral blood lymphocytes in mixed leukocyte culture. The data suggest that suppressor cells are generated in draining lymph nodes of these patients by a high concentration of tumor-derived products and may have suppressive influence on host immunologic defense mechanisms.

Carcinoma, Transitional Cell↗
PubMed1979

Hemosiderosis of urinary bladder.

We believe this is the first case of proved hemosiderosis of the bladder to be reported. The clinical presentation, radiographic findings, and cystoscopic appearance suggested a primary bladder neoplasm.

Cystoscopy↗
PubMed1979

Complications of pelvic lymphadenectomy and retropubic prostatic 125I implantation.

Pelvic lymphadenectomy was accomplished in 75 patients with localized prostatic cancer at the time of retropubic prostatic implantation with iodine-125. Twelve (16 per cent) surgical complications were encountered in 11 patients and included 1 death. Late complications which persisted six months or longer occurred in 5 (8 per cent) of 61 patients. The most serious and as yet unquantitated complication appears to be pelvic vein thrombosis and pulmonary emboli. PELVIC LYMPHADenectomy may be accomplished safely and with minimal morbidity in the vast majority of prostatic cancer patients.

Adenocarcinoma↗
PubMed1979

Malignancy in uremia: dialysis versus transplantation.

The incidence of cancer was compared in 499 dialysis patients and 121 renal transplant recipients. De novo malignancy developed in 15 patients on chronic dialysis (3 per cent) and in 6 transplant recipients (4.9 per cent), a significant increase over the expected number in the age-matched general population. There was no difference in the incidence of cancer in uremic patients on dialysis or after transplantation. A total of 10 dialysis patients (67 per cent) and 1 transplant patient (16 per cent) died of cancer. Neoplasms in the dialysis patients were the common types of mesenchymal tumors, while superficial skin cancers were seen more frequently in the transplant recipients. The differences in tumor types accounted for the higher mortality rate from cancer in the dialysis patients and may reflect different patterns of immunosuppression in these 2 patient populations.

Aged↗
PubMed1979

Preservation of sexual potency in prostatic cancer patients after pelvic lymphadenectomy and retropubic 125I implantation.

Sexual histories were obtained from 51 patients (average age 67.7 years) with prostatic cancer and their spouses before and after pelvic lymphadenectomy and retropubic 125iodine implantation. Sexual potency was retained in 40 of the 41 patients who were sexually active preoperatively. Ten patients were sexually inactive preoperatively: 4 with diminished potency and 6 with complete erectile impotence. Sexual dysfunction was most often psychogenic in origin. At 6 months 5 of these patients had resumed satisfactory sexual intercourse as a result of reassurance, encouragement and education of remaining sexual potential. No patient suffered complete erectile impotence as a result of the procedure.

Aged↗